Pharmaceuticals

Avastin (Bevacizumab) Market 2026–2030: Emerging Trends and Forecast Opportunities

March 5, 2026March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the avastin (bevacizumab) market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Avastin (Bevacizumab) Market between 2026 and 2030?

The avastin (bevacizumab) market has witnessed significant growth in recent years. It is projected to expand from $7.82 million in 2025 to $8.43 million in 2026, demonstrating a compound annual growth rate (CAGR) of 7.8%. The factors contributing to its historical growth include the clinical validation of VEGF inhibition, an increasing global cancer burden, widespread label expansion approvals, high familiarity among oncologists, and its early adoption in colorectal cancer.

The avastin (bevacizumab) market is projected for significant expansion over the coming years, reaching $11.27 million by 2030, driven by a compound annual growth rate (CAGR) of 7.5%. This anticipated growth can be credited to several factors, including the proliferation of bevacizumab biosimilars, an enlarging pool of oncology patients, greater adoption in developing markets, the necessity for economical biologics, and improved combination therapy regimens. Key developments during this period are expected to involve the sustained application of anti-angiogenic cancer treatments, the broader deployment of avastin across various cancer forms, an increase in combination therapies with chemotherapy, rising utilization in eye-related conditions, and intensified competition among biosimilars.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19879&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Avastin (Bevacizumab) Market?

The rising incidence of cancer is anticipated to fuel the expansion of the avastin (bevacizumab) market in the future. Cancer encompasses a range of illnesses marked by the uncontrolled proliferation and dissemination of irregular cells throughout the body. Its growing prevalence stems from factors like aging demographics, shifts in lifestyle, and enhanced diagnostic techniques. Avastin combats cancer by suppressing VEGF, which obstructs the formation of blood vessels crucial for supplying tumors with oxygen and nutrients, thus effectively depriving them. For example, in August 2024, Macmillan Cancer Support, a UK-based organization, stated that over 3 million individuals in the UK were living with cancer in 2024, a number expected to climb to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the escalating prevalence of cancer is propelling the growth of the avastin (bevacizumab) market. Avastin (Bevacizumab) Market Driver: Impact Of Rising Healthcare Expenditure On Avastin (Bevacizumab) Market Growth

How Is The Avastin (Bevacizumab) Market Organized Into Various Segments?

The avastin (bevacizumab) market covered in this report is segmented –

1) By Dosage: 100 Mg, 400 Mg

2) By Application: Non Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, Cervical Cancer, Colorectal Cell Cancer, Ovarian Cancer, Proliferative Diabetic Retinopathy, Malignant Glioma, Neurofibromatosis, Pancreatic Cancer, Other Applications

3) By Distribution channel: Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

4) By End User: Hospitals, Cancer Supportive Centers, Home Healthcare, Academic And Research Institutes, Other End Users

Which Trends Are Shaping Activity Within The Avastin (Bevacizumab) Market?

Key companies in the Avastin (bevacizumab) market are concentrating on the expansion of biosimilars, particularly high-profile bevacizumab biosimilars, to achieve a competitive edge. Biosimilar proliferation denotes a swift increase in the quantity and accessibility of biosimilar medicines in the market. For example, in December 2023, Bio Thera Solutions, a biopharmaceutical company based in China, obtained FDA approval for Avzivi (bevacizumab tnjn), a biosimilar to Avastin, which demonstrated comparable efficacy, safety, and immunogenicity to the reference product. Additionally, in July 2024, the European Medicines Agency (EMA) endorsed BAT1706 / Avzivi for various oncology uses. These advances are promoting greater cost-effectiveness and wider patient availability. Conversely, they also escalate pricing pressures on the originator product, contest market share, and require strong manufacturing capabilities from new participants.

Who Are The Core Companies Influencing Trends In The Avastin (Bevacizumab) Market?

Major companies operating in the avastin (bevacizumab) market are Roche Holding AG

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/avastin-bevacizumab-global-market-report

Which Regions Are Projected To Dominate The Avastin (Bevacizumab) Market In The Coming Years?

North America was the largest region in the avastin (bevacizumab) market in 2025. The regions covered in the avastin (bevacizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Avastin (Bevacizumab) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19879&type=smp

Browse Through More Reports Similar to the Global Avastin (Bevacizumab) Market 2026, By The Business Research Company

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Antiviral Combination Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795